Clinical trial
A Phase I Study of Weekly Administration of Oral Navelbine in Combination With the COX-2 Inhibitor Celebrex in Relapsed and/or Metastatic Breast Cancer
NCT00075673 is registered in ClinicalTrials.gov with Case Comprehensive Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of Weekly Administration of Oral Navelbine in Combination With the COX-2 Inhibitor Celebrex in Relapsed and/or Metastatic Breast Cancer
- Lead sponsor
- Case Comprehensive Cancer Center
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- November 30, 2003
- Completion date
- February 28, 2005
- Enrollment
- 6 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer